* Support Healthy Plasma/Tissue CoQ10 Levels
* Reduced by Aging, Clinical Conditions
* Associated With Low Plasma CoQ10 levels, Low Energy Syndromes, Genetic
* Disorders and Drugs that Interfere with CoQ10 and or Energy Production
* Support for Cardiovascular Conditions e.g.: Hypertension, Heart Failure, Angina Pectoris, Arrythmias, Acute Reperfusion Injuries and Acute Myocardial Infarction
* Support for Neuromuscular Disorders and Age Related CNS Degeneration Conditions
* Supports a Healthy Immune System
* Support for Healthy Gums
CoQ10Supreme is an all-natural, proprietary, patent-pending, crystal-free, solvent-free, lipid-stabilized CoQ10 shown in recent clinical trials to be over eight times more absorbable than powdered forms of CoQ10 and more than twice as bioavailable as other oil-based or so-called ?Nano?- dispersed formulas. CoQ10Supreme's proprietary monoglyceride carrier is a patent-pending formulation unmatched for optimal utilization in the support of cardiovascular, CNS, immune and energy-based health needs.
Coenzyme Q10 is a biologically active, natural vitamin-like substance belonging to a group of compounds called ubiquinones and structurally similar to vitamin K. It is present in animal protein and can be synthesized in the body; however a variety of factors may cause a CoQ10 deficiency.
From the 1970?s to the mid-1990?s pure crystalline (powdered) CoQ10 was the industry standard despite its poor absorption (0.6-1.0%). A variety of forms and delivery systems offering somewhat improved absorption (2.3-5%) have entered the market since 1995. However, the forms have been unstable and crystallized, a form the body cannot absorb.
CoQ10Supreme represents a new generation of CoQ10 supplements. Unlike any other in today?s market place, it is crystal-free when examined by a light microscope. This patent-pending formulation contains three lipids to aid in dissolving CoQ10 crystals into single molecules, stabilize the formula to prevent re-crystallization and facilitate passive diffusion to enhance absorption.
A full double blind randomized clinical trial in 20 normal human volunteers with a relatively controlled diet was performed to determine the absorption and steady state bioavailability characteristics.
Absorption involves several phases in the movement of CoQ10 through a portion of the digestive tract, into the lymphatics and finally into general circulation where it becomes bioavailable.
Absorption is reflected by the time base changes in the amount of CoQ10 appearing in the blood plasma after the ingestion of a single known dose. Bioavailability refers to the amount of CoQ10 accumulated in the blood plasma over an extended time of taking a known constant daily dose.
Within the trial, a 36-hour absorption study showed that CoQ10Supreme had a total absorption 783% greater than powdered CoQ10 (11.65% vs 1.32%). The bioavailability study involved measuring blood accumulation (mg) of CoQ10 over 28 days. The 28-day steady state bioavailability for CoQ10Supreme was 8.86 mg compared to 1.64 mg for the dry powder standard. The relative bioavailability showed that CoQ10Supreme was 541% more bioavailable than the standard product. The AUC (0-28 day) was 680 mg/day compared to 120 mg/day or 463% more bioavailable than the dry powder standard.
CoQ10Supreme is titanium dioxide-free making the softgel transparent and permitting verification of the crystal-free claim.
1. Berthold HK,et al. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 2006;29(8):703- 12 [PMID: 16872244]
2. Lopez-Lluch G, Barroso MP, Martin SF, Fernandez-Ayala DJ, Gomez-Diaz C, Villalba JM, Navas P. Role of plasma membrane coenzyme Q on the regulation of apoptosis. Biofactors. 1999;9(2-4):171 [PMID: 10416029]
3. Crane FL Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001 Dec;20(6):591-8
4. Rundek T, Naini A, Sacco R, Coates K, DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch Neurol. 2004 Jun;61(6):889-92 [PMID: 15210526]
5. Littarru GP, Lippa S, Oradei A, Serino F.Coenzyme Q10: blood levels and metabolic demand. Int J Tissue React. 1990;12(3):145-8. [PMID: 2276891]
6. Munkholm H, Hansen HHT, Rasmussen K: Coenzyme Q10 treatment in serious heart failure. Biofactors 1999;9(2-4): 285-289 [PMID: 10416042]
7. Eriksson JG, Forsen TJ, Mortensen SA, Rohde M: The effect of coenzyme Q10 administration on metabolic control in patients with type 2 diabetes mellitus. Biofactors 1999: 315-318 [PMID: 10416046]
8. Langsjoen PH, Langsjoen AM. Overview of the use of CoQ10 in cardiovascular disease. Biofactors. 1999;9(2-4):273-84. [PMID: 10416041]
9. Rosenfeldt F, Hilton D, Pepe S, Krum H Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors. 2003;18(1-4):91-100 [PMID: 14695924]
10. Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Curr Opin Clin Nutr Metab Care. 2005 Nov;8(6):641-6. Review. [PMID: 16205466]
11. de Lau LM. Serum cholesterol levels and the risk of Parkinson?s disease. Am J Epidemiol. 2006 Nov 15;164 (10):998-1002. Epub 2006 Aug [PMID: 16905642] Figuero E,et al. Oxidant/antioxidant interactions of nicotine, Coenzyme Q10, Pycnogenol and phytoestrogens in oral periosteal fibroblasts and MG63 osteoblasts. Steroids. 2006 Dec;71(13-14):1062-72. Epub 2006 Oct 11 [PMID: 17045317